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GBV-C/HGV-RNA in serum and peripheral blood mononu- mately 9.4 kb in length that encodes a single large poly-
clear cells in hemodialysis patients. protein. Based on the genome structure, the GBV-C/HGV
Background. Hemodialysis patients are at high risk of hepa- is classified as a new member of the Flaviviridae family,
titis B, C, and G virus infection. The prevalence of GBV-C/
distantly related to the hepatitis C virus (HCV) [1–3].HGV-RNA was analyzed in serum and peripheral blood mono-
GBV-C/HGV-RNA was found in sera from patientsnuclear cells (PBMCs) from 52 hemodialysis patients.
Methods. GBV-C/HGV-RNA detection was performed by with chronic hepatitis and in subjects with frequent par-
reverse transcription-polymerase chain reaction (RT-PCR) with enteral exposure, including intravenous drug users, bone
primers of 59-noncoding (59-NC) and NS3 regions of the GBV-C/ marrow-transplanted patients, and organ or blood recipi-
HGV genome. To increase sensitivity, serum samples were ultra-
ents [4–6]. Patients on maintenance hemodialysis are atcentrifuged prior to the RT-PCR to concentrate the viral parti-
high risk of hepatitis B, C [7–10], and G virus infection.cles. The amplified products from 20 serum and 5 peripheral
Indeed, detection of HGV-RNA has been recently re-blood mononuclear cells (PBMC) samples were sequenced.
Results. GBV-C/HGV-RNA was detected in sera of 9 (17%) ported in serum samples of hemodialysis patients, with
and in PBMCs of 30 (58%) patients. After serum ultracentrifu- a prevalence of 3 to 57% [11–14].
gation, GBV-C/HGV-RNA was positive in 20 (95%) of the pa- Replication of GBV-C/HGV in liver cells has been sug-tients, with GBV-C/HGV-RNA only in PBMCs. Thus, GBV-C/
gested [15, 16], and GBV-C/HGV has also been detectedHGV-RNA was detected in serum and PBMCs from 29 (56%)
in peripheral blood mononuclear cells (PBMCs) frompatients, four of whom had antibodies against GBV-C/HGV
E2 protein (anti-HGE2); one patient (2%) had GBV-C/HGV- patients having GBV-C/HGV-RNA in serum [15–17].
RNA only in PBMCs, but was anti-HGE2 positive. Seven However, the significance of the latter finding remains
(32%) patients who did not have GBV-C/HGV-RNA were unknown. Few data are available on the presence ofanti-HGE2 positive. The nucleotide sequence homology be-
GBV-C/HGV-RNA in PBMCs from hemodialysis pa-tween serum samples from the patients who were GBV-C/
tients. Recently, Tribl et al have analyzed the presenceHGV-RNA positive after ultracentrifugation, and paired se-
rum and PBMCs from five of them, ranged from 90 to 96% of GBV-C/HGV in sera and blood cells from this type
and from 92 to 98%, respectively. of patients [18]. However, several issues remain to be
Conclusions. We found a high prevalence of GBV-C/HGV- addressed to more completely understand the natural
RNA in serum and PBMC samples from hemodialysis patients. history of GBV-C/HGV infection in dialysis patients.Whether or not this finding can be extended to other popula-
First, the patients need to be have follow-up visits totions requires further study.
study the persistence of GBV-C/HGV-RNA in PBMCs;
second, the sequence homology between the GBV-C/
HGV-RNA isolated from serum and PBMCs needs toRecently, a new hepatitis-associated virus named hep-
be analyzed to further ascertain the diagnostic andatitis G virus (GBV-C/HGV) has been isolated [1, 2].
pathophysiologic significance of serum and PBMC mea-The viral genome is a single-stranded RNA of approxi-
surements. Our study was designed to assess these issues
in our population of hemodialysis patients.
Key words: hepatitis C virus, hepatitis B virus, serum ultracentrifuga-
tion, viral genome, Flavivirdae family, antibodies against GBV-C/HGV.
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tion of 148 patients) treated in a university hospital- contamination of the PBMCs with GBV-C/HGV-RNA
derived from blood or damaged cells. Purified and washeddependent unit were retrospectively analyzed in this
study. Patients were selected at random from those hav- PBMCs were stored in aliquots at 2808C together with
the serum sample and the last washing fluid until theing paired serum and PBMC samples properly stored at
2208C and 2808C, respectively. All but one patient (72 RNA extraction. Total RNA from serum (250 ml),
PBMCs (resuspended in 250 ml of PBS), and total lastIU/liter) had normal alanine aminotransferase (ALT)
levels at the start of the study (20 6 12 IU/liter; range, cell wash (250 ml) were isolated using the Trizol LS
Reagent (GIBCO/BRL, Gaithersburg, MD, USA) and9 to 41 IU/liter). The patients (31 men and 21 women;
mean age, 58 6 13 years) were on maintenance hemodi- were precipitated with isopropanol. The concentration
of the RNA isolated from the PBMCs was determinedalysis for a mean period of 56 6 65 months (range, 3 to
370 months). Thirty-eight (73%) of them received blood measuring its absorbance at 260 nm.
The RNA extracted from sera and last cell wash andtransfusions (mean of blood units transfused, 9 6 11;
range, 1 to 59 U). The renal diseases were glomerulone- 1 mg of PBMC-RNA were amplified using a one-step
RT-PCR method and nested PCR (GIBCO/BRL) withphritis (25 patients), interstitial nephritis (7 patients),
adult polycystic disease (5 patients), diabetic nephropa- specific primers from the 59-NC region of the HGV ge-
nome (outer primers: sense, 59-CACTGGGTGCAAGthy (4 patients), nephroangiosclerosis (2 patients), and
miscellaneous causes (9 patients). To study the persis- CCCCAGAA-39, and antisense, 59-CACTGGTCCTT
GTCAACTCG-39; and inner primers: sense, 59-CGACtence of the GBV-C/HGV-RNA, a second serum and
PBMC samples from 24 patients were taken 12 months GCCTACTGAAGTAGAC-39, and antisense, 59-CGT
CGCCTATTGGTCAAGAG-39) [3]. The sensitivity ofafter the first samples. In all cases, serum and PBMC
samples were obtained before the dialysis session, in the the PCR assay was assessed amplifying serial dilutions
of a GBV-C/HGV-RNA–known concentration obtainedabsence of heparin administration to the patients.
Ten healthy individuals without markers for any by in vitro transcription of a plasmid containing the com-
pleted 59-NC region of GBV-C/HGV cloned under theknown hepatitis viruses and who did not belong to any
risk group for viral hepatitis served as negative controls. control of the SP6-RNA polymerase promoter. The de-
tection limit for this technique ranged from 10 to 20
Serological markers genome copies per assay.
GBV-C/HGV-RNA detection in serum was also per-HBsAg, anti-HBs, anti-HBc, and anti-HDV were
tested by commercial radioimmunoassays (Abbott Lab- formed by PCR in the serum samples from 23 patients
previously tested with 59-NC primers (20 PCR negativeoratories, North Chicago, IL, USA). Anti–HIV-1 (Ab-
bott Laboratories) and anti-HCV (Ortho Diagnostics and 3 PCR positive) as reported [18] using primers de-
rived from the helicase (NS3) region of GBV-C/HGVSystems, Inc., Raritan, NJ, USA) were tested by com-
mercial enzyme-linked immunoassays (ELISA). Serum genome.
To avoid false positive results, the contamination-pre-HBV-DNA was detected by polymerase chain reaction
(PCR) using primers from the precore-core region of vention measures described by Kwok and Higuchi were
followed [20]. Appropriate negative controls, serum orthe HBV genome, as described [10]. The presence of
HCV-RNA in serum was analyzed by reverse transcrip- PBMC samples from healthy individuals, water instead
of RNA, and omission of RT/Taq mix were included intion (RT)-nested PCR, using primers from the 59-non-
coding (59-NC) region of the HCV genome, as previously each PCR assay, and each sample was tested twice by
different workers in independent experiments; in allreported [19].
Antibodies against the E2 protein of GBV-C/HGV cases, a 100% concordance was obtained.
To increase the sensitivity, PCR-negative serum sam-(anti-HGE2) were detected using a commercial kit, the
mPlate anti-HGenv enzyme-linked immunoassay (Boeh- ples from patients who were GBV-C/HGV-RNA posi-
tive by PCR in the corresponding PBMC sample wereringer Mannheim GmbH, Mannheim, Germany).
clarified by centrifugation at 12,000 r.p.m. for 10 minutes.
Serum and peripheral blood mononuclear cell The supernatant (1 ml) was layered onto a sucrose cush-
GBV-C/HGV-RNA detection ion consisting of 2 ml of 1 g/ml sucrose in TEN buffer
(50 mm Tris-HCl, pH 8.0, 1 mm ethylenediaminetetraace-Serum and heparinized peripheral blood samples were
collected at the same time before the dialysis session tic acid (EDTA), and 150 mm NaCl) and centrifuged at
50,000 r.p.m. for 24 hours at 108C in a Beckman SW60from each patient using the vacutainer system. PBMCs
(107 cells) were isolated from fresh heparinized periph- Ti rotor (Beckman Co., Palo Alto, CA, USA). The pellet
was resuspended in 250 ml of sterile distilled water, anderal blood by Ficoll-Hypaque gradient centrifugation
(Flow Laboratories, Irvine, Ayrshire, UK) and were after the isolation of total RNA, RT-PCR was performed
using 59-NC region primers, as described earlier in thiswashed three times in ice-cold phosphate-buffered saline
(PBS). The last cell wash was conserved as a control for article. Two serum samples, one GBV-C/HGV-RNA–
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positive control and one negative control from a healthy without HBV antibodies. Eight of the 27 (30%) hemodi-
alysis patients without HBV-DNA by PCR had antibod-subject, were included in each ultracentrifugation. Serum
samples from six patients without GBV-C/HGV-RNA ies against HBV. All patients were negative for hepatitis
B surface antigen (HBsAg). Anti-HCV and HCV-RNAin PBMCs were also ultracentrifuged.
by PCR were also determined: 14 patients (27%) had
Sequence analysis serum HCV-RNA (11 anti-HCV negative and 3 anti-
HCV positive), and 8 (15%) had only anti-HCV. None ofTo determine the homology between GBV-C/HGV
sequences from serum samples after ultracentrifugation, the patients had antihepatitis D virus (HDV) or human
immunodeficiency virus antibodies (anti-HIV).the amplified products corresponding to the GBV-C/
HGV 59-NC region from serum of 20 patients, positive
Detection of GBV-C/HGV-RNA in serum andto the GBV-C/HGV-RNA in serum only after ultracen-
peripheral blood mononuclear cellstrifugation, and from the PBMCs of five of these patients,
were purified using the Wizard PCR preps DNA purifi- GBV-C/HGV-RNA was detected by RT-PCR using
primers derived from the 59-NC region of the GBV-C/cation system (Promega, Madison, WI, USA) and Cy5
directly sequenced using an ALFe express DNA auto- HGV genome, in the sera of 9 of 52 (17%) hemodialysis
patients studied. However, when GBV-C/HGV-RNAmated Sequencer (Pharmacia Biotech AB, Uppsala,
Sweden). was tested in PBMCs, it was positive in 30 of 52 (58%)
samples (Fig. 1). Thus, there were 21 patients who hadNucleotide sequences were aligned with the CLUS-
TAL X program [21], and phylogenetic analysis was per- GBV-C/HGV-RNA in PBMCs but not in the corre-
sponding serum sample. The last PBS wash of the PBMCformed using the PHYLIP package [22]. Evolutionary
distances were estimated by the Kimura 2-parameters samples resulted always negative, demonstrating that the
detection of GBV-C/HGV-RNA in PBMCs was not duemethod using the DNADIST program. Phylogenetic
trees were constructed by the neighbor-joining method to serum contamination (Fig. 1). Also, PBMCs from
normal controls were always PCR negative. To confirmusing the NEIGHBOR program, TREE VIEW 1.52 pro-
gram. Analysis of 1000 bootstrap resamples of the nu- these results, GBV-C/HGV-RNA was tested in paired
serum and PBMC samples were taken 12 months aftercleotide alignment data sets was performed using the
SEQBOOT, DNADIST, NEIGHBOR, and CONSENSE the first samples from 24 patients (6 with GBV-C/HGV-
RNA in both serum and PBMC, 8 with GBV-C/HGV-software programs. A bootstrap value of 75% was con-
sidered statistically significant. RNA only in PBMCs, and 10 without GBV-C/HGV-RNA
in either serum or PBMCs). In all cases, the same results
GBV-C/HGV-RNA detection in paraffin-embedded as in the first samples were obtained. When the RT-PCR
liver biopsies was performed in 23 serum samples (3 GBV-C/HGV-
RNA positive in serum and 20 serum viral RNA nega-To assess whether or not GBV-C/HGV was also pres-
ent in the liver of the hemodialysis patients, paraffin- tive) using primers from NS3 region of the GBV-C/HGV
genome, the same results were obtained as when usingembedded liver biopsies from five patients were avail-
able. Liver sections were dewaxed in xylol for 10 minutes 59-NC region derived primers: GBV-C/HGV-RNA was
detected in the sera from three patients who were serumat 48C and rehydrated through a series of ethanol dilu-
tions. After that, total RNA was isolated using the Trizol PCR positive, whereas in the rest of the patients, the
PCR remained negative.LS reagent (GIBCO/BRL), and the GBV-C/HGV-RNA
was detected by RT-PCR as described earlier in this
Concentration of circulating viral particlesarticle.
by ultracentrifugation
Statistical analysis To increase the sensitivity of the PCR, those serum
samples from patients with GBV-C/HGV-RNA detect-Data were expressed as the mean 6 sd and analyzed
using Fisher’s exact test for comparison of proportions able only in PBMCs were ultracentrifuged before the
RNA extraction and RT-PCR to concentrate circulatingand Student’s t-test for continuous variables.
viral particles. With this technique, GBV-C/HGV-RNA
in serum was positive in 20 out of 21 (95%) who had
RESULTS
GBV-C/HGV-RNA only in PBMCs. Thus, GBV-C/
Detection of hepatitis B and C infections HGV-RNA was detected in serum and PBMC samples
from 29 of 52 (56%) hemodialysis patients, and in oneSerum samples from the patients were tested for sero-
logical markers of HBV and HCV infections. Twenty- patient (2%), GBV-C/HGV-RNA was detectable only
in PBMCs. Serum samples from six patients withoutfive (48%) of them had HBV-DNA by PCR: 10 patients
anti-HBs and anti-HBc-positive, 3 patients with anti- GBV-C/HGV-RNA detectable in PBMCs were PCR
negative after ultracentrifugation, and also, the normalHBc alone, 1 patient with anti-HBs alone, and 11 patients
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Fig. 1. Hepatitis G virus (GBV-C/HGV)-RNA amplification using primers from the 59-noncoding region (322 base pairs), from serum (S), PBMC
(P), last phosphate buffered saline (PBS) wash (W), and serum after ultracentrifugation (S’) from four hemodialysis patients: patient 1, with GBV-
C/HGV-RNA in serum and peripheral blood mononuclear cells (PBMCs); patient 2, without GBV-C/HGV-RNA; patient 3, with GBV-C/HGV-
RNA in PBMCs and in serum after ultracentrifugation; and patient 4, with GBV-C/HGV-RNA only in PBMCs. M, 100 base pair DNA ladder
(GIBCO/BRL).
control included in each ultracentrifugation was always Coinfection with hepatitis B and C viruses
PCR negative, demonstrating that the detection of GBV-C/ Eighteen of 33 (54%) hemodialysis patients with HBV
HGV-RNA after ultracentrifugation was not due to cross- markers had GBV-C/HGV-RNA in their serum; 16 of
contamination between the rotor adaptators. them were HBV-DNA positive by PCR with or without
antibodies against HBV, and 2 patients had only antibod-
Association of GBV-C/HGV-RNA with ies against the virus. With respect to the HCV-infected
clinical characteristics hemodialysis patients, GBV-C/HGV-RNA was found in
No statistical differences in age, sex, ALT levels, time 13 of 22 of them (59%): in 1 out of 8 (12%) with anti-
on hemodialysis, and renal disorders were found between HCV alone and in 12 out of 14 (86%) patients who had
GBV-C/HGV-RNA–positive and 2negative patients. The serum HCV-RNA by PCR with or without anti-HCV
number of blood units transfused was higher in patients (Table 2). No statistical differences (54 vs. 59%) in the
who had serum GBV-C/HGV-RNA than those without, prevalence of GBV-C/HGV-RNA between HBV- and
although the difference did not reach statistical signifi- HCV-infected hemodialysis patients were found. How-
cance (Table 1). ever, the prevalence of GBV-C/HGV-RNA in serum
was significantly higher in patients with HBV-DNA and/
Detection of HGE2 antibodies or HCV-RNA in serum, independently of whether or
Of the 29 patients with simultaneous detection of not they had antibodies against HBV or HCV (22/33,
GBV-C/HGV-RNA in their serum (including the 20 pa- 66%), than in patients with antibodies against both vi-
tients who were GBV-C/HGV-RNA positive in serum ruses but without HBV-DNA or HCV-RNA in serum
only after ultracentrifugation) and PBMCs, 4 (14%) had (1/8, 12%, P , 0.02).
antibodies against HGV E2 protein. The patient who
Nucleotide sequence comparison ofhad GBV-C/HGV-RNA only detectable in PBMCs was
GBV-C/HGV isolatesalso anti-HGE2 positive. Finally, anti-HGE2 antibodies
were also positive in seven (32%) of the patients who The nucleotide sequence of the 20 serum samples posi-
did not have detectable GBV-C/HGV-RNA either in tive to the GBV-C/HGV-RNA only after ultracentrifu-
serum or PBMCs. Thus, taken together, 12 (23%) of 52 gation revealed that all amplified products from the
HGV 59-NC region were GBV-C/HGV-RNA. The nu-hemodialysis patients had anti-HGE2 antibodies.
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Table 1. Basal features of serum GBV-C/HGV-RNA positive and negative hemodialysis patients
Characteristic GBV-C/HGV-RNA1 GBV-C/HGV-RNA2
Patient number 29 23
Men/women 18/11 14/9
Agea 55613 (27 to 78) 63 613 (24 to 75)
Serum ALTa (IU/liter) 2169 (9 to 42) 22 613 (12 to 72)
Dialysis timea months 54650 (8 to 240) 67 683 (12 to 370)
Blood units transfuseda 11614 (1 to 59) 6 67 (0 to 32)c
Renal disordersb
GN 17 8
DN 2 2
PD 1 4
IN 3 4
NA 2 0
MC 4 5
a Values are expressed as mean 6 sd (range)
b Abbreviations are: GN, glomerulonephritis; DN, diabetic nephropathy; PD, adult polycystic disease; IN, interstitial nephritis; NA, nephroangiosclerosis; MC,
miscellaneous causes
c Five patients never received a blood transfusion
Table 2. GBV-C/HGV coinfection with HBV or HCV, independently
GBV-C/HGV-RNA1 GBV-C/HGV-RNA2
HBV-DNA1 with or without
Antibodies (N 5 25) 16 (64%) 9 (36%)
Only antibodies against HBV (N 5 8) 2 (25%) 6 (75%)
No HBV markers (N 5 19) 11 (58%) 8 (42%)
HCV-RNA1 with or without
AntiHCV (N 5 14) 12 (86%) 2 (14%)
Only antiHCV1 (N 5 8) 1 (12%) 7 (88%)
No HCV markers (N 5 30) 16 (53%) 14 (47%)
cleotide homology between the different serum samples DISCUSSION
ranged from 90 to 96% (data not shown). On the other Serum GBV-C/HGV-RNA was detected by a nested
hand, the comparison of the GBV-C/HGV-RNA– RT-PCR technique in 17% of the hemodialysis patients
amplified products from the paired serum and PBMC analyzed, which represents an intermediate prevalence
samples of five patients shows that the homology ranged among that reported in other studies [11, 12, 23–25].
However, when the presence of GBV-C/HGV-RNA wasfrom 92 to 98% (Fig. 2). The phylogenetic tree showed
tested in the PBMC samples from the same patients, aa random distribution of the 59-NC sequences isolated
high frequency (58%) of patients with GBV-C/HGV-from 20 serum samples (Fig. 3), and no statistically sig-
RNA in PBMCs was found. Recently, Tribl et al havenificant bootstrap values were obtained in any case.
reported the detection of GBV-C/HGV-RNA in serum
and PBMC samples from hemodialysis patients [18].Detection of GBV-C/HGV-RNA in liver biopsies
These authors found GBV-C/HGV-RNA in sera of 16The presence of GBV-C/HGV-RNA by PCR was
of 119 (13%) hemodialysis patients, a prevalence similar
tested in paraffin-embedded liver tissue from five of the
to ours, but only 8 of 119 (7%) patients had GBV-C/
hemodialysis patients included in this study. Two of them HGV-RNA in the PBMCs, two of them (2%) without
had GBV-C/HGV-RNA detected in serum (without ultra- viral RNA in serum, which is a much lower percentage
centrifugation) and PBMCs, one with GBV-C/HGV- than that found in our hemodialysis population (41%
RNA positive in serum after ultracentrifugation and in of patients with GBV-C/HGV-RNA only in PBMCs).
PBMCs and two cases without GBV-C/HGV-RNA in When we applied the RT-PCR technique (with NS3
either serum or PBMCs. In the three cases with GBV-C/ primers) used previously [18] to the analysis of serum
HGV-RNA in serum, a band of the expected size was GBV-C/HGV-RNA in our hemodialysis patients, the
detected, whereas no amplification was obtained in the patients who did not have GBV-C/HGV-RNA by PCR
two liver samples from the serum GBV-C/HGV-RNA– with 59-NC primers remained GBV-C/HGV-RNA nega-
tive. We do not have a clear explanation for the discrep-negative patients.
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Fig. 2. Comparison of nucleotide sequences of 240 bp of the amplified region of the GBV-C/HGV-RNA from serum after ultracentrifugation (S)
and PBMC (P) samples from five hemodialysis (HD) patients: HD6, HD9, HD12, HD15, and HD17. The asterisks indicate 100% homology
between all GBV-C/HGV sequences.
ancy in the prevalence of GBV-C/HGV between both the inner surface of the filter membrane during dialysis,
and thus, the HCV-RNA titers decrease immediatelystudies, although it may reflect the distinct prevalence
of GBV-C/HGV infection in different countries. On the after the dialysis sessions [26, 27]. Furthermore, the half-
life of the HCV particles in serum has been estimatedother hand, this difference may be related to the time
at which blood samples were obtained. In this regard, it to be two days [28]. A similar behavior of GBV-C/HGV
can be expected, as both HCV and GBV-C/HGV belonghas been reported that HCV particles are adsorbed onto
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attached to the cell membrane. These hypotheses should
be tested in the future. According to our study, after
ultracentrifugation of serum samples prior to the RT-
PCR revealed the presence of previously undetected
GBV-C/HGV-RNA in 20 out 21 patients with GBV-C/
HGV-RNA in PBMCs. Finally, the difference found in
our dialysis population in the positivity to GBV-C/HGV-
RNA in serum and PBMC cannot be attributed to a low
sensitivity of the technique used, because when the assay
was performed with in vitro transcribed GBV-C/HGV-
RNA, it was established that the limit of detection was
similar to that described to detect HCV-RNA by PCR
[29, 30].
If the finding of this work (that the prevalence of
GBV-C/HGV-RNA is higher in PBMC than in serum)
was extended to high-risk populations other than hemo-
dialysis patients, then the real prevalence of GBV-C/
HGV infection may be underestimated. In this regard,
32% of patients without GBV-C/HGV-RNA were posi-
tive for anti-HGE2 antibodies. Therefore, considering
the patients with GBV-C/HGV-RNA either in serum or
PBMC and those only with anti-HGE2 antibodies, 71%
of our hemodialysis population might have been in con-
tact with or are infected by GBV-C/HGV. In agreement
with other reports [31–33], we found a higher prevalence
of anti-HGE2 antibodies in patients without (32%) than
in those (17%) with GBV-C/HGV-RNA in serum or
PBMCs. This result indicates that the antibody response
to recombinant HGV E2 protein might serve as a useful
Fig. 3. Unrooted phylogenetic tree of the GBV-C/HGV sequences marker for diagnosing recovery from GBV-C/HGV in-
isolated from serum after ultracentrifugation (S) samples from 20 hemo- fections.dialysis (HD) patients. The bootstrap values were not statistically sig-
With respect to the route of infection, our results ofnificant in any case.
the comparison of the nucleotide sequences of the PCR
products suggest that the GBV-C/HGV has been trans-
mitted to our hemodialysis population by blood transfu-
to the same family of viruses [3]. In our study, all samples sion, because no common sequences were found between
were taken before the dialysis session, and the patients infected patients. Furthermore, the phylogenetic analysis
received three sessions per week. Therefore, it is possible of the GBV-C/HGV-RNA sequences amplified from the
that the time elapsed from the last dialysis session to serum of different patients showed a random distribution
the phlebotomy was not enough to produce new viral without statistically significant bootstrap values, so there
particles. However, this only could explain the differ- was no common origin of the sequences, as would occur
ences in the prevalence of GBV-C/HGV-RNA in serum in a patient-to-patient spread. Indeed, the number of
but not in PBMC. Indeed, it has been recently shown blood transfusions was higher, although not significantly
that filter membranes used in hemodialysis induce the so, in patients with GBV-C/HGV-RNA than those with-
endogenous production of interferon-a (abstract; Sam- out. In this regard, the higher prevalence of GBV-C/
pietro et al, J Hepatol 28:116, 1998), which can inhibit HGV-RNA in patients with HBV and/or HCV viremia
viral replication, contributing to a decrease in the num- than in those without suggests that the three viruses have
ber of circulating viral particles. Therefore, it is possible been transmitted by the same route. In any case, this set
that either adsorption onto the filter membrane of the of data constitutes a database for pursuing the detection
GBV-C/HGV particles or the endogenous production of GBV-C/HGV determinations in the future. The ap-
of interferon-a may decrease the serum GBV-C/HGV- pearance of new cases in nontransfused individuals would
RNA concentration without affecting the GBV-C/HGV- be of great help in determining the means of dissemi-
RNA in PBMCs, because either the virus infects but nation.
does not replicate in PBMCs or the GBV-C/HGV-RNA In conclusion, we have disclosed the existence of a
high prevalence of GBV-C/HGV-RNA in serum anddetected in PBMC came from viral particles passively
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